Sensorion: collaboration on an injection system
As part of the agreement, the two partners will evaluate ways to optimize the potential delivery of gene therapy products for enhanced efficacy and flexibility in the patient.
Sensorion explains that therapies developed for the treatment of genetically-induced deafness are generally difficult to implement, as they have to be administered into the cochlea, a delicate organ embedded in the temporal bone.
For the record, Sensorion is currently developing gene therapy product candidates aimed at restoring hearing in patients suffering from hereditary monogenic forms of deafness.
Following this announcement, Sensorio shares gained 1.5% on Tuesday on the Paris Stock Exchange, after climbing more than 6% in the course of the morning.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction